- Home
- BGI vs MRKR Comparison
BGI vs MRKR Comparison
Compare BGI & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGI
- MRKR
- Stock Information
- Founded
- BGI 1879
- MRKR N/A
- Country
- BGI Canada
- MRKR United States
- Employees
- BGI N/A
- MRKR N/A
- Industry
- BGI
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- BGI
- MRKR Health Care
- Exchange
- BGI Nasdaq
- MRKR Nasdaq
- Market Cap
- BGI 15.9M
- MRKR 13.7M
- IPO Year
- BGI 2005
- MRKR N/A
- Fundamental
- Price
- BGI $0.84
- MRKR $0.90
- Analyst Decision
- BGI
- MRKR Strong Buy
- Analyst Count
- BGI 0
- MRKR 3
- Target Price
- BGI N/A
- MRKR $13.17
- AVG Volume (30 Days)
- BGI 201.0K
- MRKR 2.6M
- Earning Date
- BGI 07-25-2025
- MRKR 08-14-2025
- Dividend Yield
- BGI N/A
- MRKR N/A
- EPS Growth
- BGI N/A
- MRKR N/A
- EPS
- BGI N/A
- MRKR N/A
- Revenue
- BGI $124,446,731.00
- MRKR $5,388,071.00
- Revenue This Year
- BGI N/A
- MRKR N/A
- Revenue Next Year
- BGI N/A
- MRKR $15.82
- P/E Ratio
- BGI N/A
- MRKR N/A
- Revenue Growth
- BGI N/A
- MRKR 44.55
- 52 Week Low
- BGI $0.56
- MRKR $0.81
- 52 Week High
- BGI $2.95
- MRKR $5.95
- Technical
- Relative Strength Index (RSI)
- BGI 65.04
- MRKR 32.98
- Support Level
- BGI $0.64
- MRKR $0.81
- Resistance Level
- BGI $1.07
- MRKR $0.98
- Average True Range (ATR)
- BGI 0.08
- MRKR 0.10
- MACD
- BGI 0.02
- MRKR -0.02
- Stochastic Oscillator
- BGI 46.53
- MRKR 14.71
About BGI Birks Group Inc.
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.